Pretreatment with recombined human erythropoietin attenuates ischemia - reperfusion-induced lung injury in rats

被引:58
作者
Wu, Haiwei
Ren, Binhui
Zhu, Jiaquan
Dong, Guohua
Xu, Biao
Wang, Changtian
Deng, Xiaogang
Jing, Hua
机构
[1] Nanjing Univ, Sch Clin Med, Jingling Hosp, Dept Cardiothorac Surg, Nanjing 210002, Peoples R China
[2] Nanjing Univ, Sch Clin Med, Jingling Hosp, Dept Pathol, Nanjing 210002, Peoples R China
关键词
erythropoietin; ischemia-reperfusion injury; lung;
D O I
10.1016/j.ejcts.2006.02.036
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Based on the findings that erythropoietin (EPO) has been proved to be a multiple functional cytokine to attenuate ischemia-reperfusion (I/R) injury in various organs such as brain, heart, and kidney in animals, this experiment was designed to evaluate the effect of pretreatment with recombined human erythropoietin (rhEPO) on I/R-induced lung injury. Methods: Left lungs of rats underwent 90 min of ischemia and then were reperfused for up to 2 h. Animals were randomly divided into three experimental groups as sham group, I/R group, and rhEPO + I/R group (a single dose of rhEPO was injected intraperitoneally 3000 U/kg 24 h prior to operation). Lung injury was evaluated according to semi-quantitive analysis of microscopic changes, tissue polymorphonuclear neutrophils (PMNs) accumulation (myeloperoxidase (MPO) activity), and pulmonary microvascular permeability (Evan's blue dying method). Peripheral arterial and venous blood samples were obtained for blood-gas analysis after 5 min occlusion of right lung hilus at the end of reperfusion. The serum concentration of tumor necrosis factor (TNF)-alpha was also measured by the method of enzyme-linked immunosorbent assay. Results: Histological injury scoring revealed significantly lessened lung alveolus edema and neutrophils infiltration in the rhEPO pretreated group compared with I/R group (p < 0.05). The rhEPO pretreated animals exhibited markedly decreased lung microvascular permeability (p < 0.05) and myeloperoxidase activity (p < 0.05). Blood-gas analysis demonstrated that the pretreated animals had significantly ameliorated pulmonary oxygenation function (p < 0.05). The serum concentration of tumor necrosis factor-a in rhEPO pretreated group was markedly decreased compared with that of I/R group (p < 0.05). Conclusions: Pretreatment with rhEPO appears to attenuate I/R-induced lung injury. This function is partly related with the capacity that rhEPO inhibits the accumulation of polymorphonuclear neutrophils in lung tissue and decreases the systematic expression of tumor necrosis factor-alpha. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:902 / 907
页数:6
相关论文
共 26 条
[1]   Neutrophils and acute lung injury [J].
Abraham, E .
CRITICAL CARE MEDICINE, 2003, 31 (04) :S195-S199
[2]   Erythropoietin reduces the development of experimental inflammatory bowel disease [J].
Cuzzocrea, S ;
Mazzon, E ;
Di Paola, R ;
Patel, NSA ;
Genovese, T ;
Muià, C ;
De Sarro, A ;
Thiemermann, C .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 311 (03) :1272-1280
[3]   EVANS BLUE-DYE IN THE ASSESSMENT OF PERMEABILITY-SURFACE AREA PRODUCT IN PERFUSED RAT LUNGS [J].
DALLAL, MM ;
CHANG, SW .
JOURNAL OF APPLIED PHYSIOLOGY, 1994, 77 (02) :1030-1035
[4]  
DiSanto E, 1997, J IMMUNOL, V159, P379
[5]   Systemic interleukin 10 administration inhibits brain tumor necrosis factor production in mice [J].
DiSanto, E ;
Adami, M ;
Bertorelli, R ;
Ghezzi, P .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 336 (2-3) :197-202
[6]   INTERLEUKIN-1 AND TUMOR-NECROSIS-FACTOR-ALPHA INHIBIT ERYTHROPOIETIN PRODUCTION INVITRO [J].
FANDREY, J ;
JELKMANN, WEB .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES-SERIES, 1991, 628 :250-255
[7]   The phosphatidylserine receptor: a crucial molecular switch? [J].
Henson, PM ;
Bratton, DL ;
Fadok, VA .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2001, 2 (08) :627-633
[8]   Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-γ ligand, on lung ischemia-reperfusion injury in rats [J].
Ito, K ;
Shimada, J ;
Kato, D ;
Toda, S ;
Takagi, T ;
Naito, Y ;
Yoshikawa, T ;
Kitamura, N .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2004, 25 (04) :530-536
[9]  
JELKMANN W, 1990, CONTRIB NEPHROL, V87, P68
[10]  
Kamoshita N, 1997, J HEART LUNG TRANSPL, V16, P1062